Treatment of overweight and obesity: Lifestyle, pharmacologic, and surgical options

Clinical Cornerstone

Volumn 9, Issue 4, 2009, Pages 55-71

  Cannon, Christopher P ^a   Kumar, Amit ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMFEPRAMONE; AMPHETAMINE DERIVATIVE; ANTIOBESITY AGENT; BENZPHETAMINE; EXENDIN 4; FLUOXETINE; METFORMIN; MULTIVITAMIN; PHENDIMETRAZINE; PHENTERMINE; PLACEBO; RIMONABANT; SIBUTRAMINE; SULFONYLUREA; TARANABANT; TETRAHYDROLIPSTATIN; TOPIRAMATE; ZONISAMIDE;

ADD ON THERAPY; ANXIETY; ARTICLE; ATTENTION DISTURBANCE; BARIATRIC SURGERY; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DEPRESSION; DIARRHEA; DIET THERAPY; DIZZINESS; DRUG WITHDRAWAL; DYSLIPIDEMIA; FATIGUE; FOOD INTAKE; HEALTH CARE PLANNING; HEALTH HAZARD; HEART RATE; HEPATOBILIARY DISEASE; HUMAN; HYPERTENSION; INSOMNIA; LANGUAGE DISABILITY; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; MEMORY DISORDER; MENTAL CONCENTRATION; MORBID OBESITY; NAUSEA; NEOPLASM; NERVOUSNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSTEOARTHRITIS; PARESTHESIA; PHYSICAL ACTIVITY; PREVALENCE; PSYCHOMOTOR DISORDER; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SIDE EFFECT; SLEEP APNEA SYNDROME; STOMACH EMPTYING; SUICIDAL IDEATION; TREATMENT INDICATION; UNITED STATES; WEIGHT REDUCTION; XEROSTOMIA;

ANTI-OBESITY AGENTS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; APPETITE DEPRESSANTS; BARIATRIC SURGERY; BEHAVIOR THERAPY; CARDIOVASCULAR DISEASES; DIET; EXERCISE; HEALTH BEHAVIOR; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; METABOLIC DISEASES; OBESITY; OVERWEIGHT; WEIGHT LOSS;

EID: 70349333812     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(09)80005-7     Document Type: Article

References (81)

1. Ogden C.L., Carroll M.D., McDowell M.A., et al., the Division of Health, Nutrition Examination Surveys. Obesity among adults in the United States-no statistically significant change since 2003-2004. NCHS Data Brief (November 2007), US Dept of Health and Human Services, Centers for Disease Control and Prevention
2. York D.A., Rössner S., Caterson I., et al., the American Heart Association. Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: Group I: Worldwide demographics of obesity. Circulation 110 (2004) e463-e470
3. US Dept of Health and Human Services, National Institutes of Health, and Weight-control Information Network. Statistics related to overweight and obesity. http://win.niddk.nih.gov/statistics/index.htm#preval Accessed April 21, 2009
4. James P.T., Rigby N., Leach R., and the International Obesity Task Force. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehab. 11 (2004) 3-8
5. Hossain P., Kawar B., and El Nahas M. Obesity and diabetes in the developing world-a growing challenge [published correction appears in N Engl J Med. 2007;356:973]. N Engl J Med. 356 (2007) 213-215
6. Lissner L., and Heitmann B.L. Dietary fat and obesity: Evidence from epidemiology. Eur J Clin Nutr. 49 (1995) 79-90
7. Drewnowski A., Kurth C., Holden-Wiltse J., and Saari J. Food preferences in human obesity: Carbohydrates versus fats. Appetite. 18 (1992) 207-221
8. Gates J.C., Huenemann R.L., and Brand R.J. Food choices of obese and non-obese persons. J Am Diet Assoc. 67 (1975) 339-343
9. Cox D.N., Perry L., Moore P.B., et al. Sensory and hedonic associations with macronutrient and energy intakes of lean and obese consumers. Int J Obes Relat Metab Disord. 23 (1999) 403-410
10. Jebb S.A., and Moore M.S. Contribution of a sedentary lifestyle and inactivity to the etiology of overweight and obesity: Current evidence and research issues. Med Sci Sports Exerc. 31 Suppl (1999) S534-S541
11. Adams K.F., Schatzkin A., Harris T.B., et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 355 (2006) 763-768
12. Eckel R.H., and Krauss R.M. American Heart Association call to action: Obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation 97 (1998) 2099-2100
13. Chuang S.Y., Chou P., Hsu P.F., et al. Presence and progression of abdominal obesity are predictors of future high blood pressure and hypertension. Am J Hypertens. 19 (2006) 788-795
14. de Simone G., Devereux R.B., Chinali M., et al., the Strong Heart Study Investigators. Risk factors for arterial hypertension in adults with initial optimal blood pressure: The Strong Heart Study. Hypertension. 47 (2006) 162-167
15. Kissebah A.H., Freedman D.S., and Peiris A.N. Health risks of obesity. Med Clin North Am. 73 (1989) 111-138
16. Pouliot M.C., Després J.P., Nadeau A., et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes. 41 (1992) 826-834
17. McLaughlin T., Abbasi F., Lamendola C., and Reaven G. Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: Effect of differences in insulin sensitivity. Arch Intern Med. 167 (2007) 642-648
18. National Heart, Lung, Blood Institute in cooperation with the National Institute of Diabetes, Digestive, and Kidney Diseases. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. The Evidence Report (September 1998), National Institutes of Health, Bethesda, MD NIH publication 98-4083
19. Wadden T.A., Anderson D.A., and Foster G.D. Two-year changes in lipids and lipoproteins associated with the maintenance of a 5% to 10% reduction in initial weight: Some findings and some questions. Obes Res. 7 (1999) 170-178
20. Wing R.R., Koeske R., Epstein L.H., et al. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med. 147 (1987) 1749-1753
21. Knowler W.C., Barrett-Connor E., Fowler S.E., et al., the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 346 (2002) 393-403
22. Tuomilehto J., Lindström J., Eriksson J.G., et al., the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 344 (2001) 1343-1350
23. Buchwald H., Avidor Y., Braunwald E., et al. Bariatric surgery: A systematic review and meta-analysis [published correction appears in N Engl J Med. 2007;356:973]. JAMA. 292 (2004) 1724-1737
24. Zeyda M., and Stulnig T.M. Obesity, inflammation, and insulin resistance-A mini-review. Gerontology 55 (2009) 379-386
25. Tchernof A., Nolan A., Sites C.K., et al. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 105 (2002) 564-569
26. Snow V., Barry P., Fitterman N., et al., the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic and surgical management of obesity in primary care: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 142 (2005) 525-531
27. Sacks F.M., Bray G.A., Carey V.J., et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 360 (2009) 859-873
28. Shai I., Schwarzfuchs D., Henkin Y., et al., the Dietary Intervention Randomized Controlled Trial (DIRECT) Group. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med. 359 (2008) 229-241
29. Mente A., de Koning L., Shannon H.S., and Anand S.S. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med. 169 (2009) 659-669
30. Wing R.R. Physical activity in the treatment of the adulthood overweight and obesity: Current evidence and research issues. Med Sci Sports Exerc. 31 Suppl (1999) S547-S552
31. Foster G.D., Makris A.P., and Bailer B.A. Behavioral treatment of obesity. Am J Clin Nutr. 82 Suppl (2005) 230S-235S
32. Wadden T.A., and Foster G.D. Behavioral treatment of obesity. Med Clin North Am. 84 (2000) 441-461
33. Williamson D.A., and Perrin L.A. Behavioral therapy for obesity. Endocrinol Metab Clin North Am. 25 (1996) 943-954
34. Fujioka K., and Lee M.W. Pharmacologic treatment options for obesity: Current and potential medications. Nutr Clin Pract. 22 (2007) 50-54
35. Nisoli E., and Carruba M.O. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev. 1 (2000) 127-139
36. Cypess A.M., Lehman S., Williams G., et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med. 360 (2009) 1509-1517
37. James W.P., Astrup A., Finer N., et al. Effect of sibutramine on weight maintenance after weight loss: A randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 356 (2000) 2119-2125
38. Finer N., Bloom S.R., Frost G.S., et al. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: A randomised, double-blind, placebo- controlled study. Diabetes Obes Metab. 2 (2000) 105-112
39. Fujioka K., Seaton T.B., Rowe E., et al., the Sibutramine/ Diabetes Clinical Study Group. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2 (2000) 175-187
40. Sabuncu T., Ucar E., Birden F., and Yasar O. The effect of 1-yr sibutramine treatment on glucose tolerance, insulin sensitivity and serum lipid profiles in obese subjects. Diabetes Nutr Metab. 17 (2004) 103-107
41. Tankova T., Dakovska G., Lazarova M., et al. Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects. Acta Diabetol 41 (2004) 146-153
42. Hung Y.J., Chen Y.C., Pei D., et al. Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with type 2 diabetes. Diabet Med 22 (2005) 1024-1030
43. Faria A.N., Ribeiro Filho F.F., Kohlmann N.E., et al. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. Diabetes Obes Metab 7 (2005) 246-253
44. Maggioni A.P., Caterson I., Coutinho W., et al., the SCOUT Investigators. Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: A preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) trial. J Cardiovasc Pharmacol 52 (2008) 393-402
45. Finer N., James W.P., Kopelman P.G., et al. One-year treatment of obesity: A randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 24 (2000) 306-313
46. Hauptman J., Lucas C., Boldrin M.N., et al. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 9 (2000) 160-167
47. Sharma A.M., and Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 20 (2002) 1873-1878
48. Bakris G., Calhoun D., Egan B., et al., the Orlistat and Resistant Hypertension Investigators. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens 20 (2002) 2257-2267
49. Hanefeld M., and Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: A randomized, placebo-controlled trial. Diabetes Obes Metab 4 (2002) 415-423
50. Miles J.M., Leiter L., Hollander P., et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin [published correction appears in Diabetes Care. 2002;25:1671]. Diabetes Care. 25 (2002) 1123-1128
51. Kelley D.E., Bray G.A., Pi-Sunyer F.X., et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial [published correction appears in Diabetes Care. 2003;26:971]. Diabetes Care. 25 (2002) 1033-1041
52. Zanella M.T., Uehara M.H., Ribeiro A.B., et al. Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: The ARCOS study. Arq Bras Endocrinol Metabol 50 (2006) 368-376
53. Muls E., Kolanowski J., Scheen A., Van Gaal L., and the ObelHyx Study Group. The effects of orlistat on weight and on serum lipids in obese patients with hypercholester-olemia: A randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord 25 (2001) 1713-1721
54. Jacob S., Rabbia M., Meier M.K., and Hauptman J. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab 11 (2009) 361-371
55. Torgerson J.S., Hauptman J., Boldrin M.N., and Sjöström L. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients [published correction appears in Diabetes Care. 2004;27:856]. Diabetes Care. 27 (2004) 155-161
56. Wadden T.A., Berkowitz R.I., Womble L.G., et al. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: A placebo-controlled trial. Obes Res 8 (2000) 431-437
57. Munro J.F., MacCuish A.C., Wilson E.M., and Duncan L.J. Comparison of continuous and intermittent anorectic therapy in obesity. Br Med J 1 (1968) 352-354
58. Li Z., Maglione M., Tu W., et al. Meta-analysis: Pharmacologic treatment of obesity. Ann Intern Med 142 (2005) 532-546
59. Anderson J.W., Greenway F.L., Fujioka K., et al. Bupropion SR enhances weight loss: A 48-week double-blind, placebo-controlled trial. Obes Res 10 (2002) 633-641
60. Dolfing J.G., Wolffenbuttel B.H., ten Hoor-Aukema N.M., and Schweitzer D.H. Daily high doses of fluoxetine for weight loss and improvement in lifestyle before bariatric surgery. Obes Surg 15 (2005) 1185-1191
61. De Simone G., and Supuran C.T. Antiobesity carbonic anhy-drase inhibitors. Curr Top Med Chem 7 (2007) 879-884
62. Wilding J., Van Gaal L., Rissanen A., et al., the OBES-002 Study Group. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 28 (2004) 1399-1410
63. Stenlöf K., Rössner S., Vercruysse F., et al., the OBDM-003 Study Group. Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes. Diabetes Obes Metab 9 (2007) 360-368
64. Toplak H., Hamann A., Moore R., et al. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: A randomized, double-blind, placebo-controlled study. Int J Obes (Lond) 31 (2007) 138-146
65. Gadde K.M., Franciscy D.M., Wagner II H.R., and Krishnan K.R. Zonisamide for weight loss in obese adults: A randomized controlled trial. JAMA 289 (2003) 1820-1825
66. Van Gaal L., Pi-Sunyer X., Desprës J.P., et al. Efficacy and safety of rimonabant for improvement of multiple cardio-metabolic risk factors in overweight/obese patients: Pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 31 Suppl 2 (2008) S229-S240
67. Desprës J.P., Golay A., Sjöström L., and the Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipi-demia. N Engl J Med 353 (2005) 2121-2134
68. Scheen A.J., Finer N., Hollander P., and the RIO-Diabetes Study Group. and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study [published correction appears in Lancet. 2006;368:1650]. Lancet. 368 (2006) 1660-1672
69. Klonoff D.C., Buse J.B., Nielsen L.L., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24 (2008) 275-286
70. Moretto T.J., Milton D.R., Ridge T.D., et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study [published correction appears in Clin Ther. 2008;30:1937]. Clin Ther. 30 (2008) 1448-1460
71. Schneider B.E., and Mun E.C. Surgical management of morbid obesity. Diabetes Care 28 (2005) 475-480
72. Bult M.J., van Dalen T., and Muller A.F. Surgical treatment of obesity. Eur J Endocrinol 158 (2008) 135-145
73. Santry H.P., Gillen D.L., and Lauderdale D.S. Trends in bariatric surgical procedures. JAMA 294 (2005) 1909-1917
74. Maggard M.A., Shugarman L.R., Suttorp M., et al. Meta-analysis: Surgical treatment of obesity. Ann Intern Med 142 (2005) 547-559
75. Christou N.V., Sampalis J.S., Liberman M., et al. Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg 240 (2004) 416-423
76. MacDonald Jr. K.G., Long S.D., Swanson M.S., et al. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg 1 (1997) 213-220
77. Whitson B.A., Leslie D.B., Kellogg T.A., et al. Entero-endocrine changes after gastric bypass in diabetic and nondiabetic patients: A preliminary study. J Surg Res 141 (2007) 31-39
78. Laferrére B., Teixeira J., McGinty J., et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 93 (2008) 2479-2485
79. Ferrannini E., and Mingrone G. Impact of different bariatric surgical procedures on insulin action and beta-cell function in type 2 diabetes. Diabetes Care 32 (2009) 514-520
80. Ballantyne G.H., Farkas D., Laker S., and Wasielewski A. Short-term changes in insulin resistance following weight loss surgery for morbid obesity: Laparoscopic adjustable gastric banding versus laparoscopic Roux-en-Y gastric bypass. Obes Surg 16 (2006) 1189-1197
81. Dixon J.B., Dixon A.F., and O'Brien P.E. Improvements in insulin sensitivity and beta-cell function (HOMA) with weight loss in the severely obese. Homeostatic model assessment. Diabet Med 20 (2003) 127-134